Bio-View Ltd (TLV: BIOV)

Market Cap	35.97M
Revenue (ttm)	34.34M
Net Income (ttm)	887.00K
Shares Out	130.33M
EPS (ttm)	0.01
PE Ratio	45.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,050
Open	27.30
Previous Close	27.30
Day's Range	26.80 - 28.00
52-Week Range	21.90 - 3,550.00
Beta	0.37
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 21, 2024

About Bio-View

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company’s products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH and Karyotype samples in real-time; and Allegro Plus, an automatic imaging system, which identifies var...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1998
• Employees: 33
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BIOV

Financial Performance

In 2023, Bio-View's revenue was 34.77 million, an increase of 19.29% compared to the previous year's 29.15 million. Earnings were 383,000, a decrease of -34.75%.